• Acacia Research Corp., of Newport Beach, Calif., said its CombiMatrix unit notified Cornell Capital Partners LP that it is terminating its standby equity distribution. That agreement would have provided the company with access to as much as $50 million in an equity financing commitment.

• Albany Molecular Research Inc., of Albany, N.Y., entered a two-year natural products-based drug discovery collaboration with New York-based Bristol-Myers Squibb Co. to test samples from its natural product hit-seeking collections against multiple drug targets, with the aim of identifying compounds in a range of therapeutic areas. Specific terms were not disclosed, but includes an up-front payment, research funding and potential milestones and royalties for AMRI.

• Cobalis Corp., of Irvine, Calif., agreed to sell $3.85 million in 8 percent senior secured convertible debentures to an institutional investor via a private placement. An initial $2.5 million closing is expected on or before Dec. 26, and two additional closings of $675,000 are expected upon filing a registration statement with the SEC and upon that registration statement being declared effective. Proceeds will be used for general corporate and working capital purposes, principally the advancement of the company's clinical program for the allergy prevention drug PreHistin.

• CV Therapeutics Inc., of Palo Alto, Calif., filed for European approval of Ranexa (ranolazine) for chronic angina through an application that includes additional data and results from studies conducted after March 2004. The submission has been filed for review under that regulatory body's centralized procedure. The drug already is marketed in the U.S. for chronic angina patients who have not achieved an adequate response with other antianginal drugs.

• Digilab BioVisioN GmbH, of Hannover, Germany, identified candidate biomarkers for lung cancer using its Peptidomics Differential Peptide Display (DPD) technology platform in the first phase of a collaboration with Abbott Molecular Inc., of Des Plains, Ill. As a result, Abbott exercised its right to evaluate option candidate markers for further use and retains an option to acquire an exclusive, royalty-bearing license from Digilab to such candidate markers.

• Hana Biosciences Inc., of South San Francisco, filed a request for a special protocol assessment with the FDA for the design of a proposed registration trial for Marqibo (vincristine sulfate liposomes injection) in adults with acute lymphoblastic leukemia (ALL) in second relapse and beyond. Marqibo uses vincristine encapsulated in a rigid, lipid bilayer of sphingomyelin. Vincristine, an FDA-approved, standard chemotherapeutic used in most lymphoma and ALL regimens, is a cell-cycle specific agent with activity dependent on the duration of drug exposure.

• Introgen Therapeutics Inc., of Austin, Texas, obtained a worldwide, exclusive license to a family of patent applications from the University of Texas System M.D. Anderson Cancer Center, which covers methods and compositions of use for INGN 241 (mda-7/IL-24) with several types of available therapies, including chemotherapies, VEGF inhibitors, nonsteroidal anti-inflammatory drugs and proteasome inhibitors. INGN 241 is in a Phase II trial in advanced melanoma and a Phase III study in combination with radiation for solid tumors.

• NexMed Inc., of East Windsor, N.J., raised $8.65 million through a private stock and warrant placement to Southpoint Capital Advisors and RA Capital Management. The transdermal drug delivery firm agreed to sell about 13.3 million common shares at 65 cents apiece, and the investors also will receive five-year warrants to purchase another 5.3 million shares at an exercise price of 79 cents each. NexMed plans to use its proceeds for general corporate purposes and product development programs.

• YM BioSciences Inc., of Mississauga, Ontario, partnered its lead drug tesmilifene with TTY Biopharm Ltd., of Taipei, Taiwan, to expand its development into hepatic cancer. TTY will fully fund development costs and provide an undisclosed amount of up-front, milestone and royalty payments. In addition, TTY agreed to conduct a bridging study in the local population next year to support approval in Taiwan for metastatic breast cancer, should YM's current pivotal study be successful in that indication.

No Comments